UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

 

For the Month of September 2015

 

001-37521

(Commission File Number)

 

INTEC PHARMA LTD.

(Translation of registrant’s name into English)

 

12 Hartom Street
Har Hotzvim, Jerusalem 9777512, Israel

(+972) (2) 586-4657

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover

Form 20-F or Form 40-F.

 

Form 20-F Form 40-F

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(l): _________

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(7): _________

 

 

 

 

EXPLANATORY NOTE

 

On September 6, 2015, Intec Pharma Ltd. (the “Company”) published an immediate report in Israel reporting that, in accordance with Article 35GG(1) of the Israeli Securities Law, 5728-1968, and with the approval of the shareholders of the Company on July 16, 2015, subsequent to the date of the immediate report the Company will report in accordance with the U.S. Securities Exchange Act of 1934, as amended, in accordance with Section 5c of the Israeli Securities Law, 5728-1968.

 

A copy of the immediate report is attached as Exhibit 99.1 to this Form 6-K.

 

 

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

  Intec Pharma Ltd.
Date: September 8, 2015    
By: /s/ Zeev Weiss
    Zeev Weiss
    Chief Executive Officer
     

 

 

 

 

 

EXHIBIT INDEX

 

Exhibit No. Description
   
99.1 Intec Pharma Ltd. Immediate Report dated September 6, 2015.

 

 

 

 

 


 

 

 Exhibit 99.1

 

English Translation of Hebrew Immediate Report

 

 

 

 

Intec Pharma Ltd.

(the "Company")

 

September 6, 2015


Securities Authority Tel Aviv Stock Exchange Ltd
22 Kanfei Nisharim Street 2 Ahuzat Bait Street
Jerusalem Tel- Aviv 6525216

 

 

Dear Sir/Madam,

 

Re: Immediate Report

 

 

In accordance with Article 35GG(1) of the Securities Law, 5728-1968 and in accordance with the approval of the general meeting of the shareholders of the Company dated July 16, 2015 and the Company's report dated August 9, 2015 (Reference No. 2015-01-092187)1, the Company hereby announces the transfer of the Company to a reporting regime in accordance with the U.S. Securities Exchange Act of 1934, as amended, i.e., in accordance with Section 5c of the Securities Law, 5728-1968, and the regulations promulgated thereunder.

 

Subsequent to the date of this Immediate Report, the Company will report to the Magna all reports filed by the Company with the U.S. Securities and Exchange Commission.

 

The Company's periodic report for the year ended December 31, 2014, dated March 31, 2015 (Reference No. 2015-01-070225), first quarter report for the period ended March 31, 2015, dated May 31, 2015 (Reference No. 2015-01-035646), and second quarter report for the period ended June 30, 2015, dated August 30, 2015 (Reference No. 2015-01-108972), are incorporated herein by reference.

 

 

 

Sincerely,

Intec Pharma Ltd.

By: Zeev Weiss, CEO

By: Oren Mohar, CPA, CFO

 

 

 

 

 

 


1 See Company’s report from June 11, 2015 and July 16, 2015, Reference Nos. 2015-01-046128 and 2015-01-074997, respectively.